February 21, 2017 07:14 AM EST
Pharma

Gilead bags Sarep­ta's pri­or­i­ty re­view vouch­er for a dis­count, pay­ing $125M

John Carroll

Editor & Founder

Back in the sum­mer of 2015, Ab­b­Vie agreed to pay $350 mil­lion for a pri­or­i­ty re­view vouch­er, which can be used to shave four months …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

A look at biotech's year of the megaround

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

FDA ad­comm to re­view No­var­tis' Fab­hal­ta in ul­tra-rare kid­ney dis­ease

A service from the Financial Times